News for Collegium Pharmaceutical, Inc. (COLL)

STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. ( COLL) today announced that it will report first quarter 2025 financial r

**media[578269]**

On March 21, 2025, Scott Dreyer, Executive Vice President & Chief Commercial Officer at Collegium Pharmaceutical Inc (COLL), sold 20,808 shares of the company.

”“ Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board ”“

**media[568249]**

STOUGHTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. ( COLL) today announced it will have two poster presentations highlighting

Collegium Pharmaceutical is executing on commercializing its drugs and growing sales. Click here to find out why COLL stock is a Strong Buy.

STOUGHTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. ( COLL) today announced that management will participate in investor meeti

Collegium Pharmaceutical, Inc. reported strong Q4 results last week where the company easily beat on the bottom line and grew revenues north of 20%. Read more here.

We recently compiled a list of the 12 Best Small Cap Pharma Stocks to Buy Now. In this article, we are going to take a look at where Collegium Pharmaceutical, Inc.

Emily Field, Head of European Pharma Research at Barclays, spoke on CNBC on February 20 about the performance of obesity medications, the effects of US tariffs, and the dynamics of the pharmaceutical ...

Operator: Greetings and welcome to the Collegium Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Net Product Revenues: $181.9 million for Q4, up 22% year over year; $631.4 million for 2024, up 11% year over year.Jornay Net Revenue: $29.3 million in Q4; $10

”“ Generated Record Quarterly and Full-Year Net Revenue of $181.9 Million and $631.4 Million ”“ ”“ Reported Quarterly Jornay PM® Net Revenue of $29

**media[552841]**

PR NewswireRICHMOND, Va., Feb. 27, 2025 RICHMOND, Va., Feb. 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) has appointed Joe Ciaffoni, currently

STOUGHTON, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. ( COLL) today announced that it will report fourth quarter and full-year 20

On December 31, 2024, Invesco Ltd. (Trades, Portfolio) executed a notable transaction by acquiring an additional 289,335 shares of Collegium Pharmaceutical Inc

**media[532850]**